Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526194 | 0.86 | GAA (0.57) | GAACTBP2TDP1POLBAPEX1 | |
| SCHEMBL7038529 | 0.83 | GAA (0.47) | GAACTBP2TDP1POLBAPEX1 | |
| SCHEMBL4642049 | 0.81 | GAA (0.48) | GAACTBP2TDP1POLBAPEX1 | |
| SCHEMBL27762917 | 0.80 | CA2 (0.58) | CTBP2RAB9ALMNAKMT2AKDM4E | |
| SCHEMBL28221360 | 0.80 | GAA (0.52) | GAACTBP2TDP1POLBAPEX1 | |
| SCHEMBL2251562 | 0.80 | RAB9A (0.50) | CTBP2TDP1POLBEGFRERBB2 | |
| SCHEMBL27675295 | 0.80 | GAA (0.52) | GAACTBP2TDP1POLBAPEX1 | |
| SCHEMBL5163933 | 0.80 | GAA (0.52) | GAACTBP2TDP1POLBAPEX1 | |
| SCHEMBL11174125 | 0.79 | FFAR1 (0.51) | ALDH1A1KDM4E | |
| SCHEMBL7359518 | 0.79 | VNN1 (0.45) | GAACTBP2TDP1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | STEMSYNERGY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| CN-105646331-A | Piperidine compounds, pharmaceutical composition comprising the same and its use | 爱思开生物制药株式会社 | 2016-06-08 | — | — | CN | disclosed |
| EP-2291377-B1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2015-02-18 | — | — | EP | disclosed |
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AUTOIMMUNE PHARMA LLC | 2014-01-16 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1206474-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001016138-A1 | SULFONYLPHENYLPYRAZOLE COMPOUNDS USEFUL AS COX-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4717725-A | SPIROCYCLIC AROMATIC IMIDES | ALCON LABORATORIES, INC. (US) | 1988-01-05 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LTA4H, ALOX5AP | GAA 2031/4885CTBP2 1632/4885TDP1 1518/4885 |
| US-20230183215-A1 | Notch Inhibitors and Uses Thereof | NOTCH1, NOTCH2, NOTCH4 | GAA 3445/4885CTBP2 1260/4885TDP1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.